BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 24218361)

  • 1. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.
    Freiser ME; Serafini P; Weed DT
    Immunol Res; 2013 Dec; 57(1-3):52-69. PubMed ID: 24218361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The promise of immunotherapy in head and neck squamous cell carcinoma.
    Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
    Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor immune microenvironment in head and neck cancers.
    Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
    Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology and immunology of cancer stem(-like) cells in head and neck cancer.
    Qian X; Ma C; Nie X; Lu J; Lenarz M; Kaufmann AM; Albers AE
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):337-45. PubMed ID: 25907739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunology and Immunotherapy of Head and Neck Cancer.
    Ferris RL
    J Clin Oncol; 2015 Oct; 33(29):3293-304. PubMed ID: 26351330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising systemic immunotherapies in head and neck squamous cell carcinoma.
    Gildener-Leapman N; Ferris RL; Bauman JE
    Oral Oncol; 2013 Dec; 49(12):1089-96. PubMed ID: 24126223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for head and neck cancer patients: shifting the balance.
    Turksma AW; Braakhuis BJ; Bloemena E; Meijer CJ; Leemans CR; Hooijberg E
    Immunotherapy; 2013 Jan; 5(1):49-61. PubMed ID: 23256798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
    Moskovitz JM; Moy J; Seiwert TY; Ferris RL
    Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma.
    Almokadem S
    Curr Mol Pharmacol; 2016; 9(3):226-230. PubMed ID: 26177644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
    Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
    Zolkind P; Dunn GP; Lin T; Griffith M; Griffith OL; Uppaluri R
    Oral Oncol; 2017 Aug; 71():169-176. PubMed ID: 27751760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
    Watermann C; Pasternack H; Idel C; Ribbat-Idel J; Brägelmann J; Kuppler P; Offermann A; Jonigk D; Kühnel MP; Schröck A; Dreyer E; Rosero C; Nathansen J; Dubrovska A; Tharun L; Kirfel J; Wollenberg B; Perner S; Krupar R
    Clin Cancer Res; 2021 Jan; 27(2):632-644. PubMed ID: 33109740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Schoppy DW; Sunwoo JB
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Farlow JL; Brenner JC; Lei YL; Chinn SB
    Oral Oncol; 2021 Sep; 120():105420. PubMed ID: 34218062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment.
    Nisar S; Yousuf P; Masoodi T; Wani NA; Hashem S; Singh M; Sageena G; Mishra D; Kumar R; Haris M; Bhat AA; Macha MA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic Approaches to Head and Neck Cancer.
    Nasser H; St John M
    Crit Rev Oncog; 2018; 23(3-4):161-171. PubMed ID: 30311572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.